Ira Glick
Psychiatry · Stanford, CANPI 1245367507
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 30.2% of the total.
Across 8 payments — averaging $57.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$140
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$104
- Lundbeck LLC$89
- Avanir Pharmaceuticals, Inc.$73
- Merck$35
- Alkermes, Inc.$23
Across 466 payments — averaging $5156.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$774K
- Axsome Therapeutics, Inc.$355K
- Janssen Research & Development, LLC$212K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$191K
- Pfizer$178K
- Alkermes, Inc.$111K
- plus $582K from 13 others
What the payments were for
- Food & beverage$463100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 3 | $140 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $104 |
| Lundbeck LLC | 1 | $89 |
| Avanir Pharmaceuticals, Inc. | 1 | $73 |
| Merck | 1 | $35 |
| Alkermes, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$463 in reported general payments places this provider in the 65th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clozapine | 27 | $4,720 |
| Quetiapine Fumarate | 12 | $1,649 |
| Imipramine Hcl | 12 | $224 |
| Risperidone | 17 | $113 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Stanford
- Bibi DasStanford$1.4M
- Alan SchatzbergStanford$219K
- Maurice OhayonStanford$113K
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.